Durable responses in aRCC, how do we optimise treatment?

Perspectives on advance care planning for advanced cancer in the Philippines

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC

Preview: World Cancer Congress 2024

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer

Administering systemic chemotherapy improves survival for patients with resectable CRCLM

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant